Germline BAP1 mutations predispose to malignant mesothelioma-Reference-Cited by-同舟云学术

Germline BAP1 mutations predispose to malignant mesothelioma

Published:2011-08-28 Issue:10 Volume:43 Page:1022-1025
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Testa Joseph R,Cheung Mitchell,Pei Jianming,Below Jennifer E,Tan Yinfei,Sementino Eleonora,Cox Nancy J,Dogan A Umran,Pass Harvey I,Trusa Sandra,Hesdorffer Mary,Nasu Masaki,Powers Amy,Rivera Zeyana,Comertpay Sabahattin,Tanji Mika,Gaudino Giovanni,Yang Haining,Carbone Michele

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.912.pdf

Reference31 articles.

1. Carbone, M. et al. Malignant mesothelioma: Facts, myths and hypotheses. J. Cell. Physiol., doi:10.1002/jcp.22724 (published online 16 March 2011).

2. Flores, R.M. et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J. Thorac. Cardiovasc. Surg. 135, 620–626 (2008).

3. Tweedale, G. Asbestos and its lethal legacy. Nat. Rev. Cancer 2, 311–315 (2002).

4. Kamp, D.W. Asbestos-induced lung diseases: an update. Transl. Res. 153, 143–152 (2009).

5. Moolgavkar, S.H., Meza, R. & Turim, J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control 20, 935–944 (2009).

Cited by 911 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma;Nature Communications;2024-08-21

2. Advances in Molecular Mechanisms of Kidney Disease: Integrating Renal Tumorigenesis of Hereditary Cancer Syndrome;International Journal of Molecular Sciences;2024-08-21

3. Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity;Cellular Oncology;2024-08-14

4. Mesothelioma: molecular pathology and biomarkers;Die Pathologie;2024-08-07

5. The deubiquitinase BAP1 and E3 ligase UBE3C sequentially target IRF3 to activate and resolve the antiviral innate immune response;Cell Reports;2024-08